Skip to main content
OpenTrials
Completed

NCT Number: NCT02362724

Evaluation of Investigational (Frequent Replacement) FRP Lens for Daily Wear

The purpose of the study is to compare the investigational contact lens to a marketed contact lens.

The study results were not used for design validation of investigational contact lens,

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ametropia Eye Diseases Refractive Errors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Eric M White OD, Inc., San Diego, California, United States

Loading trial locations.

About this study

The objective of this evaluation is to provide evidence supporting the claim that the performance of the Test Lens is substantially equivalent to that of the Control Lens when used in a one month (up to 30 days) recommended replacement, daily wear modality.

The study results were not used for design validation of investigational contact lens,

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Prior to being considered eligible to participate in this study, each subject MUST:
  • Be at least 18 years of age as of the date of evaluation for the study.
  • Have:
  • Read the Informed Consent
  • been given an explanation of the Informed Consent
  • indicated understanding of the Informed Consent
  • signed the Informed Consent document.
  • Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
  • Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study.
  • Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.
  • Be in good general health, based on his/her knowledge.
  • Require spectacle lens powers between -0.50 and -8.00 diopters sphere with no more than 1.50 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes.
  • Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
  • To be eligible for lens dispensing, the subject must achieve 20/30 VA or better in each eye with the study lens and the investigator must judge the fit as acceptable or optimal.

Exclusion criteria

  • Subjects may not be enrolled in this study if any of the following apply: The subject is currently or has:
  • Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
  • Poor personal hygiene.
  • Any active participation in another clinical trial during this trial or within 30 days prior to this study.
  • To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months.
  • A member, relative or household member of the investigator or of the investigational office staff.
  • Has a known sensitivity to the ingredients used in the MPS approved for use in the study and is unable or unwilling to use the alternate care system.
  • Previous refractive surgery; or current or previous orthokeratology treatment.
  • Is aphakic or psuedophakic.
  • Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes.
  • The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day.
  • The presence of clinically significant (grade 2, 3 or 4) anterior segment abnormalities; or the presence of any inflammations such as iritis; or any infection of the eye, lids, or associated structures.
  • A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections.
  • A history of papillary conjunctivitis that has interfered with contact lens wear.
  • Slit lamp findings that would contraindicate contact lens wear, including but not limited to:
  • Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > Grade 2
  • Pterygium
  • Corneal scars within the visual axis
  • Neovascularization or ghost vessels > 1.0 mm in from the limbus
  • Giant papillary conjunctivitis (GPC) of > Grade 2
  • Anterior uveitis or iritis
  • Seborrheic eczema, seborrheic conjunctivitis or blepharitis

Treatment and study plan

Sapphire

Device

silicone hydrogel contact lens

Pearl

Device

silicone hydrogel contact lens

Primary outcomes

  1. Slit Lamp Findings for Epithelial Edema

    Time frame: Baseline (After lens dispensing)

    Slit Lamp Findings for Epithelial Edema on a grade of 0-4 (0 NONE: No microcysts; normal transparency, 1 TRACE: 1 to 20 microcysts; barely discernible local epithelial haziness, 2 MILD: 21 to 50 microcysts; faint but definite localized or generalized haziness, 3 MODERATE: 51 to 100 microcysts; significant localized or generalized haziness, 4 SEVERE: >100 microcysts; definite widespread epithelial cloudiness giving a dull glass appearance to the cornea, or numerous coalescing bullae)

  2. Slit Lamp Findings for Epithelial Edema

    Time frame: 1 Month

    Slit Lamp Findings for Epithelial Edema on a grade of 0-4 (0 NONE: No microcysts; normal transparency, 1 TRACE: 1 to 20 microcysts; barely discernible local epithelial haziness, 2 MILD: 21 to 50 microcysts; faint but definite localized or generalized haziness, 3 MODERATE: 51 to 100 microcysts; significant localized or generalized haziness, 4 SEVERE: >100 microcysts; definite widespread epithelial cloudiness giving a dull glass appearance to the cornea, or numerous coalescing bullae)

  3. Slit Lamp Findings for Stromal Edema

    Time frame: Baseline (After lens dispensing)

    Slit Lamp Findings for Stromal Edema on a grade of 0-4 (0 NONE: No edema, 1 TRACE: Just detectable clouding, 2 MILD: Faint corneal striae (2 or fewer), 3 MODERATE: Pronounced corneal striae (3), 4 SEVERE: Folds in Descemet's membrane and >4 pronounced striae)

  4. Slit Lamp Findings for Stromal Edema

    Time frame: 1 month

    Slit Lamp Findings for Stromal Edema on a grade of 0-4 (0 NONE: No edema, 1 TRACE: Just detectable clouding, 2 MILD: Faint corneal striae (2 or fewer), 3 MODERATE: Pronounced corneal striae (3), 4 SEVERE: Folds in Descemet's membrane and >4 pronounced striae)

  5. Slit Lamp Findings for Corneal Infiltrates

    Time frame: Baseline (After lens dispensing)

    Slit Lamp Findings for Corneal Infiltrates - Present, Absent

  6. Slit Lamp Findings for Corneal Infiltrates

    Time frame: 1 Month

    Slit Lamp Findings for Corneal Infiltrates - Present, Absent

  7. Slit Lamp Findings for Corneal Vascularization

    Time frame: Baseline (After lens dispensing)

    Slit Lamp Findings for Corneal Vascularization on a grade 0-4 (0 NONE: No vessel penetration, 1 TRACE: <1.00 mm vessel penetration, 2 MILD: >1.00 mm to <1.50 mm vessel penetration, 3 MODERATE: >1.50 mm to <2.00 mm vessel penetration, 4 SEVERE: Vessel penetration >2.00 mm)

  8. Slit Lamp Findings for Corneal Vascularization

    Time frame: 1 month

    Slit Lamp Findings for Corneal Vascularization on a grade 0-4 (0 NONE: No vessel penetration, 1 TRACE: <1.00 mm vessel penetration, 2 MILD: >1.00 mm to <1.50 mm vessel penetration, 3 MODERATE: >1.50 mm to <2.00 mm vessel penetration, 4 SEVERE: Vessel penetration >2.00 mm)

  9. Slit Lamp Findings for Limbal Hyperemia

    Time frame: Baseline (After lens dispensing)

    Slit Lamp Findings for Limbal Hyperemia on a grade 0-4 (0 NONE: No hyperemia present, 1 TRACE: Slight regional hyperemia, 2 MILD: Diffuse hyperemia, 3 MODERATE: Marked regional or diffuse hyperemia, 4 SEVERE: Diffuse episcleral or scleral hyperemia)

  10. Slit Lamp Findings for Limbal Hyperemia

    Time frame: 1 month

    Slit Lamp Findings for Limbal Hyperemia on a grade 0-4 (0 NONE: No hyperemia present, 1 TRACE: Slight regional hyperemia, 2 MILD: Diffuse hyperemia, 3 MODERATE: Marked regional or diffuse hyperemia, 4 SEVERE: Diffuse episcleral or scleral hyperemia)

  11. Slit Lamp Findings for Bulbar Hyperemia

    Time frame: Baseline (After lens dispensing)

    Slit Lamp Findings for Bulbar Hyperemia on a grade 0-4 (0 NONE: No hyperemia present, 1 TRACE: Slight regional hyperemia, 2 MILD: Diffuse hyperemia, 3 MODERATE: Marked regional or diffuse hyperemia, 4 SEVERE: Diffuse episcleral or scleral hyperemia)

  12. Slit Lamp Findings for Bulbar Hyperemia

    Time frame: 1 month

    Slit Lamp Findings for Bulbar Hyperemia on a grade 0-4 (0 NONE: No hyperemia present, 1 TRACE: Slight regional hyperemia, 2 MILD: Diffuse hyperemia, 3 MODERATE: Marked regional or diffuse hyperemia, 4 SEVERE: Diffuse episcleral or scleral hyperemia)

  13. Slit Lamp Findings for Palpebral Conjunctiva

    Time frame: Baseline (After lens dispensing)

    Slit Lamp Findings for Palpebral Conjunctiva - Present, Absent

  14. Slit Lamp Findings for Palpebral Conjunctiva

    Time frame: 1 month

    Slit Lamp Findings for Palpebral Conjunctiva - Present, Absent

  15. Slit Lamp Findings for Other Findings

    Time frame: Baseline (After lens dispensing)

    Slit Lamp Findings for Other findings (conjunctival infection, corneal ulcers, iritis, lens adhesions and recurrent erosion) on a grade 0-4 (0 NONE, 1 TRACE, 2 MILD, 3 MODERATE, 4 SEVERE)

  16. Slit Lamp Findings for Other Findings

    Time frame: 1 month

    Slit Lamp Findings for Other findings (conjunctival infection, corneal ulcers, iritis, lens adhesions and recurrent erosion) on a grade 0-4 (0 NONE, 1 TRACE, 2 MILD, 3 MODERATE, 4 SEVERE)

Sponsors and collaborators

Lead sponsor

CooperVision, Inc.

Industry

Registry information

Official study title

Evaluation of the CooperVision, Inc. Sapphire and Pearl Silicone Hydrogel Daily Wear Contact Lenses When Used for Frequent Replacement for Up to One (1) Month of Daily Wear.

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Feb 13, 2015
Registry last updated
Oct 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.